Next Article in Journal
Impact of Antibiotic-Loaded PMMA Spacers on the Osteogenic Potential of hMSCs
Next Article in Special Issue
Characterization of Antibiotic Treatment among Children Aged 0–59 Months Hospitalized for Acute Bacterial Gastroenteritis in Israel
Previous Article in Journal
The Antimicrobial Efficacy of Topically Applied Mafenide Acetate, Citric Acid and Wound Irrigation Solutions Lavanox and Prontosan against Pseudomonas aeruginosa
Previous Article in Special Issue
Comparative Meropenem Pharmacodynamics and Emergence of Resistance against Carbapenem-Susceptible Non-Carbapenemase-Producing and Carbapenemase-Producing Enterobacterales: A Pharmacodynamic Study in a Hollow-Fiber Infection Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 13
Issue 1
10.3390/antibiotics13010043
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Exploring Structure–Activity Relationships of Niclosamide-Based Colistin Potentiators in Colistin-Resistant Gram-Negative Bacteria

by
Liam Berry
1,
Quinn Neale
1,
Rajat Arora
1,
Danyel Ramirez
1,
Marc Brizuela
1,
Ronald Domalaon
1,
Gilbert Arthur
2 and
Frank Schweizer
1,3,*
1
Department of Chemistry, University of Manitoba, Winnipeg, MB R3T 2N2, Canada
2
Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB R3E 3N4, Canada
3
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
*
Author to whom correspondence should be addressed.
Antibiotics 2024, 13(1), 43; https://doi.org/10.3390/antibiotics13010043
Submission received: 12 December 2023 / Revised: 22 December 2023 / Accepted: 28 December 2023 / Published: 3 January 2024
(This article belongs to the Special Issue Antibiotics Use and Therapy in Gram-Negative Bacterial Infection)
Browse Figures
Versions Notes

Abstract

:
Colistin is primarily used as a last resort antibiotic against highly resistant Gram-negative bacteria (GNB). Rising rates of colistin resistance, however, may limit future use of this agent. The anthelmintic drug niclosamide has been shown to enhance colistin activity in combination therapy, but a detailed structure–activity relationship (SAR) for niclosamide against GNB has yet to be studied. A series of niclosamide analogs were synthesized to perform an SAR, leading to the discovery of a lead compound that displayed comparable colistin-potentiating activity to niclosamide with reduced cytotoxicity. Overall, this work provides important insights into synthetic strategies for the future development of new niclosamide derivatives and demonstrates that toxicity to mammalian cells can be reduced while maintaining colistin potentiation.

1. Introduction

The widespread and ever-increasing threat of antimicrobial-resistant (AMR) “superbugs” presents a significant danger to the healthcare system and to the entire world [1,2]. Indeed, a substantial increase in infections caused by AMR Gram-negative bacteria (GNB) has led to the increase in usage of last resort antibiotics such as colistin. However, rising rates of colistin resistance have resulted in bacterial infections that are resistant to all currently used antibiotics, leading to the deaths of several patients [3]. If no new treatments for these challenging infections are developed, humanity may be left with no effective agents with which to eradicate these “superbugs”.
A significant barrier to the development of new antibiotics is the challenging and costly drug approval process [4]. This combined with limited return on investment for treating rare AMR infections has stagnated the development of new antibiotics [5]. One method to overcome this significant challenge is to repurpose existing FDA-approved drugs towards the fight against AMR bacteria [6]. The already established toxicity and pharmacokinetic profiles of these drugs may streamline and potentially truncate the development and approval process for such agents, rendering a quick pathway for their much needed use in the clinic. An example of such is the anthelmintic drug niclosamide approved for the treatment of tapeworm infections, which has been shown to exhibit antibacterial activity against Gram-positive bacteria [7], inhibit quorum sensing in Gram-negative bacteria [8], and able to synergize with colistin against GNB [9] to combat the development of colistin resistance.
Despite being a promising candidate for repurposing as a drug against AMR infections, niclosamide has notable limitations. In particular, niclosamide has an extremely poor bioavailability primarily due to its low solubility [10]. Toxicity to mammalian cells has also been observed which has spurred interest in repurposing niclosamide as an anticancer agent [11] but is a significant hindrance for developing it as a selective and safe antibacterial agent. In order to further develop niclosamide as an adjuvant capable of augmenting colistin and overcome colistin resistance, new derivatives must be synthesized, and their structure–activity relationships need to be studied. Several publications have reported new niclosamide analogs for combating colistin resistance [12], as well as a detailed mechanistic understanding of niclosamide in combination with colistin [13].
The aim of this study is to synthesize derivatives of niclosamide with the goal of reducing toxicity to human cells while retaining synergy with colistin. Niclosamide is composed of a 5-chlorosalicylic acid ring linked to a 2-chloro-4-nitroaniline ring via an amide bond. The nitro group has been demonstrated to contribute to genotoxicity [14], as well as serving as a target for bacterial nitroreductases resulting in resistance to niclosamide [13]. These factors, in addition to reports that structurally similar salicylanilides such as rafoxanide (Figure 1) which lack the nitro group can also synergize with colistin [15], led to us targeting this site for most of our modifications. Our initial synthetic goal was the replacement of the nitro group with an amide moiety, which would allow rapid synthesis of a small library of amide analogs incorporating various functional groups. We also explored attaching azide and alkyne functional groups to the niclosamide scaffold with the goal of producing a small library of triazole-containing compounds via copper-assisted azide-alkyne cycloaddition (CuACC) [16].
In this work, it was found that the nitro group in niclosamide could be replaced with a methyl ester, an azide, or (to a lesser extent) a primary amine while retaining synergy with colistin against colistin-resistant GNB. We also show that replacement of the nitro group can result in new derivatives of niclosamide with lower cytotoxicity against human cells. Overall, this work provides important insights towards future development and optimization of niclosamide for overcoming colistin resistance.

2. Results and Discussion

2.1. Chemistry

The nitro group on niclosamide was chosen as an initial site for modification. We initially sought to synthesize two series of amide analogs, one of which linked the amide to the salicylanilide scaffold via the nitrogen and one that was linked via the carbonyl group. The first series of derivatives resulted from treating niclosamide with zinc dust in the presence of NH4Cl, yielding primary amine derivative 1. As an initial proof of concept, the amine was further acylated and alkylated to produce compounds 2 and 3 (Scheme 1).
The other series of amide containing compounds was synthesized by coupling commercially available 5-chlorosalisylic acid with various aniline derivatives. A methyl ester derivative 5a was synthesized via PCl3 coupling. Ester hydrolysis with LiOH produced carboxylic acid analogue 6 which was intended to serve as a scaffold to produce a small library of amide analogues (Scheme 2 and Scheme 3).
Initial attempts to derivatize acid 6 via amide coupling proved unsuccessful with analysis revealing the phenol in niclosamide posing synthetic challenges. Two phenol protecting group strategies were developed to overcome this challenge: a methyl ether protecting group that could be deprotected using BBr3 and a benzyl protecting group that could be deprotected with catalytic hydrogenolysis. The role of the phenol functional group was also explored using intermediate 5b, analogous to 5a but with a methyl ether protected phenol. These protecting group strategies enabled the development of amide derivatives 7–12 which allowed for the introduction of a variety of functional groups (Scheme 3).
An azide derivative 4 was also prepared by reacting 5-chlorosalisylic acid with 4-azidoaniline in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC). Attempts to synthesize an ethynylaniline derivative with an alkyne at the same position as the azide group proved unsuccessful, so an alternative strategy to install the alkyne group was utilized. Compound 13, a propargylamide derivative, was coupled to various azide-containing fragments via copper-assisted azide-alkyne cycloaddition (CuAAC) [16] in Scheme 4 to explore the effects of a triazole moiety in compounds 14–17.
Lastly, a series of polyphenol derivatives were synthesized (Scheme 5). Since the phenol group on niclosamide was previously shown to be essential for its activity as a protonophore [17] and thus its synergy with colistin [13], we wanted to explore the effect of installing additional phenol groups. The salicylic acid ring of niclosamide was modified with additional hydroxyl groups (18, 19) and the previously described amide coupling method was used to produce polyphenol analogs 20 and 21.

2.2. Biological Evaluations

2.2.1. Initial Screen for Synergy with Colistin and SAR

The initial screen of our study aimed to evaluate the ability of compounds 1–21 to synergize with colistin. For the initial screen, two colistin-resistant clinical isolates of Klebsiella pneumoniae (KP113250 and KP113254) and Escherichia coli (EC94393 and EC94474) were chosen. The two K. pneumoniae strains were chosen as they are highly colistin-resistant with minimum inhibitory concentrations (MIC) for colistin of 256 μg/mL. The two E. coli strains were selected as they were known to harbor the mcr-1 gene [18] which confers colistin resistance via phosphoethanolamine transferase [19]. Colistin had MICs of 8 μg/mL in EC94394 and 16 μg/mL in EC94474.
To ensure any biological activity seen was due to colistin potentiation and not to any innate activity of the newly synthesized compounds, we first screened all compounds for standalone antibacterial activity against these four strains (Table S1). The lowest concentration of each compound able to inhibit bacterial growth was determined to be the MIC. Similar to niclosamide, all compounds displayed poor antibacterial activity with MIC values of ≥128 μg/mL and were then further evaluated for synergy with colistin.
To perform the initial screen, we used a fixed concentration of 4 μM of compound and determined the MIC of colistin in combination against each strain. As a comparison, niclosamide was shown to drastically enhance the antibacterial activity of colistin in all four strains, consistent with previous reports [9]. At 4 μM, niclosamide was able to lower the MIC of colistin by 512-fold against KP113250, 1024-fold against KP113254, and 32-fold against both E. coli strains. The prominent colistin MIC reduction by niclosamide provided a baseline of potentiating activity to which the new derivatives could be compared. At first, we investigated colistin potentiation for compounds 1–3 at 4 μM (Table 1). We observed that the conversion of the nitro group to an amine moiety (1) resulted in comparable potentiation of colistin in E. coli strains. However, reduced potentiation was observed against K. pneumoniae. Further modifying the amine with acylation (2) or alkylation (3) led to a complete loss of colistin-potentiating activity against both bacteria (Table 1).
We next replaced the nitro group on niclosamide with an azide (4), a methyl ester (5a), a carboxylic acid (6), various amide moieties (7–12), and triazole fragments (14–17) (Table 2). We observed that the azide and methyl ester derivatives retained synergy with colistin against all strains tested, indicating that these modifications are compatible with the colistin potentiation of niclosamide. Compound 4 displayed prominent potentiating activity against the two E. coli strains, reducing the MIC of colistin to 0.016 μg/mL against EC94393 (a 16-fold higher reduction compared to niclosamide). As 4 also contains hydrogen at R1 instead of a chlorine atom, it appears that the chlorine at this position is not necessary for synergy with colistin. Compound 5a, in combination with colistin, displayed a comparable synergy profile relative to niclosamide in all tested strains. Interestingly, compound 5b, which differs from 5a only by a methylated phenol group, lost all synergy with colistin (Table S2). This demonstrates the necessity of the phenol in niclosamide’s ability to potentiate colistin. Unfortunately, further modification of the methyl ester moiety by converting it to a carboxylic acid (6) or an amide (7–12) completely abolished all synergy with colistin. The triazole analogs 14–17 were not able to potentiate colistin in all tested strains. Nonetheless, these findings demonstrated that the nitro group on niclosamide can be replaced with a variety of substituents while still retaining synergy with colistin.
Given the demonstrated importance of the phenol moiety within the salicylanilide scaffold, we wondered how the installation of additional phenol groups, as in compounds 18–21, would affect niclosamide’s ability to potentiate colistin (Table 3). We observed that the addition of even one additional phenol group on the salicylic acid ring (18) resulted in a complete loss of synergy with colistin. The amide-containing polyphenol compounds 20 and 21 were also inactive. These results suggest that while the phenol group is necessary, the addition of multiple phenol groups reduces colistin-potentiating activity.
Overall, the results of this SAR led to us conclude that the nitro group in niclosamide can be replaced with an azide, a methyl ester, and (to a lesser extent) an amine while still retaining synergy with colistin against GNB. We also show that further modification of the amine or ester groups abolishes synergistic activity. The phenol group was shown to be necessary for synergy with colistin as methylation resulted in complete loss of colistin potentiation (compound 5b, Table S2).
Finally, we compared the colistin potentiation of hit compounds 1, 4 and 5a to niclosamide in a panel of colistin-resistant and colistin-susceptible GNB using the checkerboard assay (Figure 2). The fractional inhibitory concentration index (FICI) for each combination was determined to assess interactions between the two components. FICI values of ≤0.5, 0.5 < x ≤ 4, and >4 were interpreted as synergistic, additive, and antagonistic interactions, respectively. We observed that compound 4 was overall superior to niclosamide (lowest FICI value), especially in E. coli. Compound 5a was comparable to niclosamide, while compound 1 showed synergy with colistin only in E. coli and K. pneumoniae but not in Pseudomonas aeruginosa. Despite the promising colistin-potentiating activity of 4, the high synthetic cost as well as concerns over the stability of the aryl azide led to us selecting the methyl ester compound 5a for further screening against clinical isolates of P. aeruginosa and Acinetobacter baumannii.

2.2.2. Synergy between 5a and Colistin against P. aeruginosa and A. baumannii

We further evaluated the therapeutic potential of lead compound 5a in combination with colistin against a panel of multidrug-resistant (MDR) clinical isolates of P. aeruginosa and A. baumannii (Table 4 and Table 5). Compound 5a was able to synergize with colistin in 8 out of 10 strains of P. aeruginosa. Synergy was only not observed in PA259 and PA260, which were already highly susceptible to colistin (MIC of 0.25 μg/mL). Analog 5a was able to drastically reduce colistin’s MIC against all colistin-resistant isolates (PA91433, PA101243, PA262 and PA101885). The combination of 5a and colistin against PA101243 was of particular note, with 1 μg/mL of 5a lowering the MIC of colistin from 1024 μg/mL to 0.5 μg/mL, a 2048-fold reduction. In all strains tested, 5a was able to lower the MIC of colistin to 0.5 μg/mL or less (Table 4).
Similar synergistic activity was observed for A. baumannii (Table 5). Synergy was observed in four out of five isolates, LAC-4 (colistin MIC of 0.25 μg/mL) being the only exception. Compound 5a was able to lower the MIC of colistin to 0.5 μg/mL or below in all strains tested, including against highly resistant AB027 (colistin MIC of 1024 μg/mL).
Overall, these results show that a combination of colistin and 5a is effective against K. pneumonia, E. coli, P. aeruginosa and A. baumannii. Replacing the nitro group of niclosamide with a methyl ester led to the development of a new derivative that synergized with colistin in nearly all clinical isolates tested, and restored colistin activity against every colistin-resistant isolate.

2.2.3. Cytotoxicity of 1 and 5a against Eukaryotic Cells

Toxicity against eukaryotic cells is a major challenge for repurposing niclosamide as an antibacterial agent. To test whether the modification of the nitro group may be a potential avenue for reducing toxicity, the toxic effects of compounds 1 and 5a were investigated on two ovarian cancer cell lines OVCAR-3 and COV362, and compared to niclosamide which has been shown to possess potent antitumor effects against ovarian cancer cells [20]. The results of experiments with the three compounds using the CyQuant assay [21] are displayed in Figure 3. After 48 h incubation, the cell number for the controls increased by about 26% for OVCAR-3 and 89% for COV362 relative to the initial cell number (day 0).
Incubation with 6–100 μM niclosamide after 48 h showed a toxic effect on both the cell lines, killing around 60% (OVCAR-3) and 30% (COV362) of the initial cell number before drug treatment. Incubation of cells with compound 5a at 6–50 μM killed only 20% of OVCAR-3 cells while it had a cytostatic effect (no significant change in initial cell number) in the same concentration range in COV362 cells. On the other hand, compound 1 at 6–50 μM showed slight inhibition of proliferation (around 13%) in OVCAR-3 cells relative to the control whereas under the same incubation conditions at 6–25 µM in COV362 cells, it stimulated proliferation and increased the cell number by 14% more than the control. Thus, in both OVCAR-3 and COV362 cells, incubation with compound 1 resulted in cell numbers higher than the initial cell number indicating a non-cytotoxic effect in the range of 6–25 μM.
Compound 5a and compound 1 at 100 μM killed 43% and 15% of OVCAR-3 cells, respectively. At the same concentration, in COV362 cells, compound 5a and compound 1 showed 75% and 66% inhibition of proliferation relative to the control but the cell numbers were still higher than the initial cell number indicating an antiproliferative rather than a cytotoxic effect. Taken together, the results demonstrate that compounds 1 and 5a are less cytotoxic than niclosamide at all concentrations tested. Since the results of the microbiological studies demonstrate that compound 5a was able to synergize with colistin to eradicate colistin-resistant GNB strains tested at concentrations of 1μg/mL (~0.3 μM), these results are very promising as an initial demonstration of reduced cytotoxicity. Overall, these results show that the replacement of the nitro group in niclosamide is a viable strategy to reduce toxicity against eukaryotic cells while retaining synergy with colistin.

3. Materials and Methods

3.1. Materials

Reagents and solvents were purchased from commercially available suppliers such as Sigma-Aldrich (St Louis, MO, USA), AK Scientific (Union City, CA, USA), Fisher Scientific (Waltham, MA, USA), and Bachem (Bubendorf, Switzerland) and were used without further purification. Air- and moisture-sensitive reactions were performed with dry solvents under inert nitrogen atmosphere. The reaction progress was monitored using thin-layer chromatography (TLC) plates visualized with UV light. Column chromatography was performed to purify the compounds using SiliaFlash P60 (40–63 μm) 60 Å silica gel from Silicycle (Quebec City, QC, Canada). The chemical structures of all final products used for biological testing were characterized by nuclear magnetic resonance spectroscopy (1H NMR and 13C NMR) on a Bruker AMX NMR 300 MHz and 500 MHz spectrometer (Bruker, Billerica, MA, USA). Electrospray ionization mass spectrometry (ESI-MS) data were obtained using a Varian 320-MS LC/MS (Agilent, Santa Clara, CA, USA).

3.2. Synthetic Methods

General Synthetic Procedures

General procedure A: Benzanilide coupling using PCl3
The appropriate benzoic acid derivative (1 equiv.) and aniline derivative (1 equiv.) were dissolved in dry xylene (2 mL per mmol of reactants) and heated to reflux. PCl3 (0.4 equiv.) was added dropwise upon which a precipitate formed. Solution was refluxed for 4 h. The mixture was cooled to rt and filtered, after which the precipitate was washed with ethyl acetate.
General procedure B: LiOH Ester hydrolysis
The appropriate carboxylic acid was dissolved in a THF (5 mL per mmol) and MeOH (5 mL per mmol) mixture. A solution of 2M LiOH in water (10 mL per mmol) was added and the reaction was stirred at rt for 2 h. The reaction was neutralized with concentrated HCl at 0 °C upon which the product precipitated, was filtered and washed with water (3 × 10 mL).
General procedure C: Amide coupling using TBTU
The appropriate carboxylic acid (1 equiv.), N-methylmorpholine (3 equiv.), and O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) (1.1 equiv.) were dissolved in anhydrous DMF (3 mL per mmol of carboxylic acid) and stirred at rt for 15 min under N2. The appropriate amine (1.2 equiv.) was added and the reaction was stirred for 4 h at rt. Solution was concentrated in vacuo and the residue was collected in DCM, washed with 1M HCl (×3), saturated NaHCO3 (×3) and brine. The organic layer was concentrated and the product was purified using flash chromatography (0–10% MeOH in DCM).
General procedure D: Methoxy deprotection
The appropriate methoxy protected intermediate (1 equiv.) was dissolved in anhydrous DCM at 0 °C. A 1M solution of BBr3 in DCM (1.5 equiv. BBr3 per methoxy group) was added dropwise and the reaction was slowly warmed to rt. Solution was stirred overnight. The reaction was cooled to 0 °C and quenched with the careful addition of MeOH (5 mL per mmol) followed by stirring for 15 min. The reaction mixture was concentrated in vacuo and the product was purified using flash chromatography (0–10% MeOH in DCM).
General procedure E: Benzyl deprotection
The appropriate benzyl protected intermediate (1 equiv.) was dissolved in MeOH (3 mL per mmol) and THF (1 mL per mmol) Palladium on carbon (0.1 equiv.) was then added followed by H2 gas (balloon). The solution was stirred for 2 h at rt, filtered over celite and concentrated in vacuo. The product was purified using flash chromatography (0–10% MeOH in DCM).
General procedure F: Copper-assisted azide-alkyne cycloaddition (CuAAC)
The appropriate azide (1 equiv.) and alkyne (1 equiv.) and CuI·P(OEt)3 (0.3 equiv.) were dissolved in anhydrous DMF (3 mL) and treated with iPr2NEt (2 equiv.) The reaction was stirred under N2 at rt for 2 h. The reaction mixture was concentrated under vacuum, dissolved in water and extracted with DCM (× 3) The organic layers were combined, dried over anhydrous Na2SO4, and concentrated in vacuo. The product was purified using flash chromatography (0–10% MeOH in DCM).
(1) N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide
Niclosamide (1.435 g, 4.38 mmol) was suspended in 25 mL of 1:1 MeOH/THF, followed by the addition of 10 mL of saturated NH4Cl (aq). Zinc dust (3 g, 45.89 mmol) was slowly added into the solution at 0 °C. The reaction was warmed to RT and stirred for 4 h, after which TLC indicated that the starting material was completely consumed. The solution was filtered over celite to remove excess zinc and the resulting filtrate was concentrated in vacuo. The crude residue was dissolved in 30 mL ethyl acetate and washed with water (3 × 10 mL) and brine (3 × 5 mL). The organic layer was concentrated and purified by flash chromatography (0–10% MeOH in DCM) yielding 649.5 mg (2.19 mmol, 49.9%) of compound 1 as a pale yellow solid. 1H NMR (500 MHz, Methanol-d4) δ 8.64 (d, J = 8.9 Hz, 1H), 8.02 (d, J = 2.7 Hz, 1H), 7.56 (d, J = 2.5 Hz, 1H), 7.41–7.37 (m, 2H), 6.97 (d, J = 8.8 Hz, 1H). 13C NMR (126 MHz, Methanol-d4) δ 163.49, 155.16, 136.00, 133.39, 130.08, 126.86, 124.82, 124.55, 123.72, 123.19, 122.03, 119.42, 118.14. ESI-MS: M/Z [M+H]+ 297.0193.
(2) N-(4-acetamido-2-chlorophenyl)-5-chloro-2-hydroxybenzamide
Compound 1 (88 mg, 0.3 mmol) was dissolved in 3 mL DCM followed by the addition of Et3N (125 µL, 0.9 mmol) and acetyl chloride (25 µL, 0.36 mmol). Solution was stirred at RT overnight and concentrated in vacuo. The crude residue was dissolved in 5 mL ethyl acetate and washed with saturated NaHCO3 (3 × 5 mL) and brine (3 × 3 mL). The organic layer was dried over anhydrous Na2SO4, concentrated and purified by flash chromatography (0–10% MeOH in DCM) yielding 86.6 mg (0.25 mmol, 84.8%) 2 off-white powder.1H NMR (500 MHz, DMSO-d6) δ 10.88 (s, 1H), 10.76 (s, 1H), 8.24 (d, J = 8.9 Hz, 1H), 8.01 (d, J = 2.3 Hz, 1H), 7.97 (d, J = 2.8 Hz, 1H), 7.58 (dd, J = 9.0, 2.4 Hz, 1H), 7.47 (dd, J = 8.8, 2.8 Hz, 1H), 7.32 (d, J = 8.8 Hz, 1H), 2.07 (s, 3H). 13C NMR (126 MHz, DMSO- d6) δ 169.14, 163.02, 156.37, 137.21, 133.54, 130.32, 129.98, 123.99, 123.57, 123.51, 119.99, 119.75, 119.59, 118.44, 24.37. ESI-MS: M/Z [M+H]+ 339.0312.
(3) 3-chloro-4-(5-chloro-2-hydroxybenzamido)-N,N,N-trimethylanilinium
Compound 1 (250 mg, 0.85 mmol) was dissolved in 5 mL DMF. 2,6 lutidine (186 µL, 1.6 mmol) was added followed by iodomethane (211 µL, 3.4 mmol). Solution was stirred at RT overnight and 20 mL ethyl acetate was added to facilitate precipitation. Product was washed on-filter with ethyl acetate (3 × 5 mL), acetone (3 × 5 mL) and DCM (3 × 5 mL) yielding 142 mg (0.41 mmol, 49%) 3 as a dark brown solid. 1H NMR (500 MHz, DMSO-d6) δ 12.38 (s, 1H), 11.17 (s, 1H), 8.67 (d, J = 8.7 Hz, 1H), 8.22 (d, J = 2.2 Hz, 1H), 8.05–7.92 (m, 2H), 7.49 (d, J = 8.75 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 3.56 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 166.14, 155.73, 143.25, 136.31, 132.87, 130.21, 129.98, 123.99, 123.57, 123.62, 119.87, 118.92, 118.01, 56.87. ESI-MS: M/Z [M+H]+ 339.0661.
(4) N-(4-azidophenyl)-5-chloro-2-hydroxybenzamide
5-Chlorosalicylic acid (45 mg, 0.293 mmol) and EDC (112 mg, 0.586 mmol) were dissolved in tetrahydrofuran (2 mL) at room temperature and stirred for 15 min.
4-Azidoaniline (51 mg, 0.299 mmol) was added and the reaction mixture was stirred at rt for 5 h over which time the solution gradually turned from clear to yellow. The reaction was concentrated under vacuo and dissolved in 12 mL ethyl acetate, washed with 1 M HCl (3 × 5 mL), saturated sodium bicarbonate solution (3 × 5 mL) and brine (3 × 5 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The crude material was purified using flash chromatography using DCM as a solvent system to afford 4 as a brown solid (61 mg, 73%) 1H NMR (500 MHz, DMSO-d6) δ 11.81 (s, 1H), 10.47 (s, 1H), 7.93 (d, J = 2.6 Hz, 1H), 7.76 (dd, J = 9.0, 2.9 Hz, 2H), 7.48 (dd, J = 8.8, 2.6 Hz, 1H), 7.16–7.13 (m, 2H), 7.02 (d, J = 8.8 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 177.32, 165.42, 157.41, 143.04, 135.53, 133.49, 128.77, 122.63, 122.60, 119.67, 119.63.
(5a) methyl 3-chloro-4-(5-chloro-2-hydroxybenzamido)benzoate
Compound 5a was synthesized following general procedure A starting from 5-Chlorosalicylic acid (928 mg, 5.38 mmol) and methyl 4-amino-3-chlorobenzoate (1 g, 5.38 mmol) and purified by flash chromatography (0–10% MeOH in DCM) resulting in 748 mg (2.2 mmol, 41%) 5a as a white solid. 1H NMR (500 MHz, DMSO-d6) δ 12.37 (s, 1H), 11.14 (s, 1H), 8.67 (d, J = 8.7 Hz, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.98–7.92 (m, 2H), 7.50 (dd, J = 8.7, 2.8 Hz, 1H), 7.08 (d, J = 8.8 Hz, 1H), 3.85 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.15, 162.85, 155.55, 139.79, 134.15, 130.46, 130.35, 129.55, 125.99, 124.14, 122.81, 121.53, 120.09, 119.53, 52.75. ESI-MS: M/Z [M+H]+ 340.0148.
(5b) methyl 3-chloro-4-[(5-chloro-2-methoxybenzoyl)amino]benzoate
Compound 5b was synthesized following general procedure A starting from 5-Chloro-2-methoxybenzoic Acid (558 mg, 3 mmol) and methyl 4-amino-3-chlorobenzoate (516 g, 3 mmol) resulting in 840 mg (2.4 mmol, 82%) of 5b as a white solid. 1H NMR (300 MHz, Chloroform-d) δ 10.80 (s, 1H), 8.81 (d, J = 8.8 Hz, 1H), 8.29 (d, J = 2.8 Hz, 1H), 8.12 (d, J = 2.0 Hz, 1H), 8.05–7.94 (m, 1H), 7.50 (dd, J = 8.9, 2.8 Hz, 1H), 7.02 (d, J = 8.9 Hz, 1H), 4.12 (s, 3H), 3.94 (s, 3H). 13C NMR (75 MHz, Chloroform-d) δ 165.69, 162.19, 155.90, 139.56, 133.55, 132.37, 130.48, 129.49, 127.19, 125.90, 122.47, 120.84, 113.11, 56.77, 52.33. ESI-MS: M/Z [M+H]+ 354.0292.
(5c) methyl 4-{[2-(benzyloxy)-5-chlorobenzoyl]amino}-3-chlorobenzoate
Compound 5a (100 mg, 0.3 mmol) was dissolved in 3 mL anhydrous DMF under N2 at 0 °C. NaH (13 mg, 0.32 mmol) as a 60% dispersion in mineral oil was added and the solution was stirred at 0 °C for 15 min. Benzyl bromide (39 µL, 0.32 mmol) was added dropwise and the solution was warmed to RT and stirred for 4 h. The reaction was quenched with 10 mL 1M HCl (aq) at 0 °C which caused the product to precipitate. The precipitate was filtered and washed with 3 × 5 mL hexanes yielding 107 mg of 5c as a pale-yellow solid (0.25 mmol, 83%) which was used without further purification.
(6) 3-chloro-4-(5-chloro-2-hydroxybenzamido)benzoic acid
Compound 6 was obtained using general procedure B starting from 5a (708 mg, 2.1 mmol) in 98% (667 mg) yield as a white powder. 1H NMR (300 MHz, DMSO-d6) δ 11.38 (s, 1H), 8.61 (d, J = 8.6 Hz, 1H), 7.95 (d, J = 1.9 Hz, 1H), 7.91–7.86 (m, 2H), 7.53–7.45 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 166.09, 163.06, 156.65, 139.29, 133.87, 130.44, 130.13, 129.57, 123.32, 122.61, 121.43, 120.09, 119.86. ESI-MS: M/Z [M+H]+ 327.1365.
(6b) 3-chloro-4-[(5-chloro-2-methoxybenzoyl)amino]benzoic acid
Compound 6b was obtained using general procedure B starting from 5b (820 mg, 2.3 mmol) in 96% (779 mg) yield as a white powder which was used without further purification.
(6c) 3-chloro-4-{[2-(benzyloxy)-5-chlorobenzoyl]amino}- benzoic acid
Compound 6c was obtained using general procedure B starting from 5c (107 mg, 0.25 mmol) in 96% (100 mg) yield as a white powder which was used without further purification.
(7) 5-chloro-N-[2-chloro-4-(methylcarbamoyl)phenyl]-2-hydroxybenzamide
Compound 7 was obtained using general procedure C starting from 6b (200 mg, 0.6 mmol) and methylamine HCl, followed by general procedure D resulting in 119 mg (0.35 mmol) of white powder (58% over 2 steps). 1H NMR (500 MHz, DMSO-d6) δ 12.33 (s, 1H), 11.05 (s, 1H), 8.54 (dd, J = 22.9, 7.1 Hz, 2H), 8.05–7.96 (m, 2H), 7.86 (d, J = 8.7 Hz, 1H), 7.52 (dd, J = 8.7, 2.5 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 2.79 (d, J = 4.2 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.19, 162.96, 155.68, 137.82, 134.11, 131.29, 130.40, 128.56, 127.31, 124.11, 123.10, 121.85, 120.16, 119.59, 26.75. ESI-MS: M/Z [M+H]+ 339.0287.
(8) methyl [3-chloro-4-(5-chloro-2-hydroxybenzamido)benzamido]acetate
Compound 8 was obtained using general procedure C starting from 6b (200 mg, 0.6 mmol) and glycine methyl ester HCl, followed by general procedure D resulting in 132 mg (0.33 mmol) of white powder (55% over 2 steps). 1H NMR (500 MHz, DMSO-d6) δ 12.36 (s, 1H), 11.10 (s, 1H), 9.06 (t, J = 5.8 Hz, 1H), 8.61 (d, J = 8.6 Hz, 1H), 8.03 (m, 2H), 7.92 (dd, J = 8.6, 2.1 Hz, 1H), 7.53 (dd, J = 8.7, 2.8 Hz, 1H), 7.10 (d, J = 8.7 Hz, 1H), 4.03 (s, 2H), 3.67 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 170.74, 165.25, 162.97, 155.67, 138.30, 134.14, 130.42, 130.26, 128.78, 127.61, 124.13, 123.09, 121.82, 120.15, 119.59, 52.25, 41.72. ESI-MS: M/Z [M+H]+ 397.0324.
(9) methyl (4S)-5-amino-4-[3-chloro-4-(5-chloro-2-hydroxybenzamido)benzamido]-5-oxopentanoate
Compound 9 was obtained using general procedure C starting from 6b (200 mg, 0.6 mmol) and L-Glutamic Acid γ-Methyl Ester α-Amide Hydrochloride followed by general procedure D resulting in 146 mg (0.31 mmol) of white powder (52% over 2 steps). 1H NMR (500 MHz, DMSO-d6) δ. 12.42 (s, 1H), 11.09 (s, 1H), 8.51 (m, 2H), 8.09 (s, 1H), 7.92 (m, 2H), 7.42 (m, 2H), 6.09 (m, 2H) 4.32 (m, 1H), 3.52 (s, 1H), 2.23 (m, 2H), 1.98 (m, 1H), 1.78 (m, 1H). 13C NMR (126 MHz, DMSO-d6) δ 173.61, 173.32, 165.05, 163.04, 155.90, 138.07, 134.11, 130.78, 130.39, 129.03, 124.94, 123.98, 122.90, 121.66, 120.15, 119.65, 53.18, 51.80, 30.77, 27.28. ESI-MS: M/Z [M+H]+ 468.0712.
(10) (4S)-5-amino-4-[3-chloro-4-(5-chloro-2-hydroxybenzamido)benzamido]-5-oxopentanoic acid
Compound 10 was obtained using general procedure B starting from 9 (100 mg, 0.21 mmol) resulting in 78 mg (0.17 mmol) of off-white powder (81%). 1H NMR (500 MHz, Methanol-d4) δ 8.65 (d, J = 8.6 Hz, 1H), 8.05 (d, J = 2.7 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.86 (dd, J = 8.7, 2.0 Hz, 1H), 7.41 (dd, J = 8.7, 2.8 Hz, 1H), 6.98 (d, J = 8.7 Hz, 1H), 4.58 (dd, J = 9.2, 5.0 Hz, 1H), 2.48 (t, J = 7.4 Hz, 2H), 2.26–2.20 (m, 1H), 2.12–2.05 (m, 1H). 13C NMR (126 MHz, Methanol-d4) δ 175.29, 175.07, 166.73, 163.32, 155.04, 138.27, 133.35, 130.22, 129.86, 128.44, 126.60, 124.87, 123.16, 121.17, 119.70, 118.10, 53.27, 30.06, 26.79. ESI-MS: M/Z [M+H]+ 454.0515.
(11) 5-chloro-N-(4-{[(2S)-1,4-diamino-1-oxobutan-2-yl]carbamoyl}phenyl)-2-hydroxybenzamide
Compound 11 was obtained using general procedure C starting from 6c (100 mg, 0.3 mmol) and L-diaminobutyric acid γ- Carbobenzoxy-α-Amide hydrochloride followed by general procedure E resulting in 43 mg (0.10 mmol) of brown powder (34% over 2 steps). 1H NMR (500 MHz, DMSO-d6) δ 12.52–12.43 (m, 1H), 11.12 (s, 1H), 8.71 (d, J = 7.8 Hz, 1H), 8.60 (d, J = 8.4 Hz, 1H), 8.14 (s, 1H), 7.99 (d, J = 2.3 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.77–7.69 (m, 3H), 7.57–7.50 (m, 2H,), 7.23 (s, 1H, 12-b), 7.12 (d, J = 8.6 Hz, 1H), 4.51–4.46 (m, 1H), 2.92–2.85 (m, 2H), 2.11 (dd, J = 14.1, 6.8 Hz, 1H), 1.96 (dd, J = 14.6, 7.3 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 173.09, 165.18, 163.00, 155.72, 138.15, 134.17, 130.62, 130.38, 129.09, 128.02, 124.09, 122.87, 121.64, 120.12, 119.62, 51.44, 36.97, 29.97 ESI-MS: M/Z [M+H]+ 425.0761.
(12) (2S)-2-[3-chloro-4-(5-chloro-2-hydroxybenzamido)benzamido]pentanedioic acid
Compound 12 was obtained using general procedure C starting from 6c (100 mg, 0.3 mmol) and Di-tert-butyl (S)-2-Aminopentanedioate hydrochloride followed by general procedure E and then general procedure B resulting in 22 mg (0.05 mmol) of white powder (15% over 3 steps). 1H NMR (500 MHz, Methanol-d4) δ 8.73 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 2.1 Hz, 1H), 7.86–7.79 (m, 2H), 7.08 (dd, J = 8.8, 3.1 Hz, 1H), 6.67 (d, J = 8.9 Hz, 1H), 4.39 (dd, J = 8.3, 4.4 Hz, 1H), 2.35–2.21 (m, 3H), 2.13–2.08 (m, 1H). 13C NMR (126 MHz, Methanol-d4) δ 180.97, 177.83, 168.80, 167.48, 166.23, 139.73, 132.64, 129.31, 128.45, 128.32, 128.25, 125.99, 123.53, 120.97, 119.21, 116.99, 56.06, 34.39, 29.03. ESI-MS: M/Z [M+Na]+ 477.0291.
(13) 5-chloro-N-{2-chloro-4-[(prop-2-yn-1-yl)carbamoyl]phenyl}-2-hydroxybenzamide
Compound 13 was obtained using general procedure C starting from 6b 500 mg, 1.5 mmol) and propargylamine followed by general procedure D resulting in 267 mg (0.74 mmol) of white powder (49% over 2 steps) which was used without further purification.
(14) methyl {4-[({3-chloro-4-[(5-chloro-2-hydroxybenzoyl)amino]benzoyl}amino)ethyl]-1H-1,2,3-triazol-1-yl}acetate
Compound 14 was obtained using general procedure F starting from 13 (55 mg, 0.15 mmol) and ethyl 2-azidoacetate resulting in 23 mg (0.05 mmol) of off-white powder (33%).1H NMR (300 MHz, DMSO-d6) δ 12.35 (s, 1H), 11.08 (s, 1H), 9.16 (t, J = 5.8 Hz, 1H), 8.58 (d, J = 8.7 Hz, 1H), 8.08 (d, J = 2.0 Hz, 1H), 8.00–7.88 (m, 3H), 7.53 (dd, J = 8.7, 2.8 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 5.35 (s, 2H), 4.54 (d, J = 5.7 Hz, 2H), 4.17 (q, J = 7.1 Hz, 2H), 1.22–1.18 (m, 3H). 13C NMR (126 MHz, DMSO-d6) δ 167.72, 164.75, 162.95, 155.66, 145.45, 138.06, 134.13, 130.81, 130.40, 128.77, 127.59, 124.93, 124.11, 123.04, 121.76, 120.14, 119.58, 61.88, 50.74, 35.33, 14.44. ESI-MS: M/Z [M+H]+ 492.0779.
(15) {4-[({3-chloro-4-[(5-chloro-2-hydroxybenzoyl)amino]benzoyl}amino)methyl]-1H-1,2,3-triazol-1-yl}acetic acid
Compound 15 was obtained using general procedure B starting from 13 (15 mg, 0.03 mmol) resulting in 12 mg (0.025 mmol) of off-white powder (86%).1H NMR (500 MHz, DMSO-d6) δ 11.29 (s, 1H), 9.17 (t, J = 5.8 Hz, 1H), 8.59 (d, J = 8.7 Hz, 1H), 8.08 (d, J = 2.0 Hz, 1H), 7.97 (d, J = 3.1 Hz, 2H), 7.92 (dd, J = 8.6, 2.0 Hz, 1H), 7.50 (dd, J = 8.7, 2.9 Hz, 1H), 7.11 (dd, J = 9.2, 5.0 Hz, 1H), 5.21 (s, 2H), 4.53 (d, J = 5.7 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 164.81, 163.13, 156.33, 145.34, 138.19, 134.03, 130.68, 130.31, 128.77, 127.57, 124.86, 123.63, 122.97, 121.68, 119.79, 53.08, 35.33. ESI-MS: M/Z [M+H]+ 464.0523.
(16) {4-[({3-chloro-4-[(5-chloro-2-hydroxybenzoyl)amino]benzoyl}amino)methyl]-1H-1,2,3-triazol-1-yl}benzoic acid
Compound 16 was obtained using general procedure F starting from 13 (55 mg, 0.15 mmol) and 4-azido benzoic acid resulting in 42 mg (0.08 mmol) of off-white powder (53%). 1H NMR (500 MHz, DMSO-d6) δ 13.20 (s, 1H), 12.52 (s, 1H), 11.12 (s, 1H), 9.23 (s, 1H), 8.82 (d, J = 7.1 Hz, 1H), 8.59 (d, J = 8.5 Hz, 1H), 8.16–8.06 (m, 5H), 8.03–7.93 (m, 2H), 7.52 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 8.4 Hz, 1H), 4.63 (d, J = 5.5 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 166.83, 164.96, 164.87, 138.09, 134.09, 131.55, 131.52, 130.94, 130.35, 128.87, 127.72, 124.00, 122.96, 121.85, 121.69, 121.19, 120.13, 35.38. ESI-MS: M/Z [M+H]+ 526.0617.
(17) 3-{4-[({3-chloro-4-[(5-chloro-2-hydroxybenzoyl)amino]benzoyl}amino)methyl]-1H-1,2,3-triazol-1-yl-phenyl}propionic acid
Compound 17 was obtained using general procedure F starting from 13 (55 mg, 0.15 mmol) and 3-(4-Azidophenyl)propanoic acid resulting in 51 mg (0.09 mmol) of off-white powder (61%). 1H NMR (500 MHz, DMSO-d6) δ 12.36 (s, 1H), 12.17 (s, 1H), 11.09 (s, 1H), 9.17 (t, J = 5.6 Hz, 1H), 8.66 (s, 1H), 8.59 (d, J = 8.7 Hz, 1H), 8.11 (d, J = 1.9 Hz, 1H), 8.02–7.93 (m, 2H), 7.81 (d, J = 8.1 Hz, 2H), 7.53 (dd, J = 8.9, 2.8 Hz, 1H), 7.44 (d, J = 8.1 Hz, 2H), 7.10 (d, J = 8.7 Hz, 1H), 4.62 (d, J = 5.4 Hz, 2H), 2.90 (t, J = 7.6 Hz, 2H), 2.60 (t, J = 7.6 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 174.07, 164.81, 162.96, 155.67, 146.37, 141.97, 138.04, 135.33, 134.12, 130.86, 130.39, 130.07, 130.07, 128.85, 127.69, 124.10, 123.02, 121.74, 121.61, 120.38, 120.37, 120.14, 119.58, 35.40, 35.36, 30.24. ESI-MS: M/Z [M+H]+ 554.0965.
(18) N-(2-chloro-4-nitrophenyl)-2,4-dihydroxybenzamide
Compound 18 was obtained using general procedure A starting from 2,4-Dimethoxybenzoic acid (182mg, 1 mmol) and 2-chloro-4-nitro aniline (172 mg, 1 mmol) followed by general procedure D, resulting in 120 mg (0.39 mmol) pale orange powder (39% over 2 steps)1H NMR (500 MHz, DMSO-d6) δ 11.99 (s, 1H), 11.21 (s, 1H), 10.31 (s, 1H), 8.86 (d, J = 9.2 Hz, 1H), 8.42 (d, J = 2.6 Hz, 1H), 8.28 (dd, J = 9.3, 2.6 Hz, 1H), 7.89 (d, J = 8.6 Hz, 1H), 6.49–6.43 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 164.27, 163.42, 158.44, 142.44, 142.38, 133.45, 125.23, 124.35, 122.32, 120.77, 110.04, 109.17, 103.10. ESI-MS (negative mode): M/Z [M−H]− 307.0388.
(19) N-(2-chloro-4-nitrophenyl)-2,4,5-trihydroxybenzamide
Compound 19 was obtained using general procedure A starting from 2,4,5-Trimethoxybenzoic acid (212 mg, 1 mmol) and 2-chloro-4-nitro aniline (172 mg, 1 mmol) followed by general procedure D, resulting in 175 mg (0.54 mmol) pale yellow powder (54% over 2 steps) 1H NMR (500 MHz, DMSO-d6) δ 11.26 (s, 2H), 9.88 (s, 1H), 8.83–8.80 (m, 2H), 8.35 (d, J = 2.6 Hz, 1H), 8.21 (dd, J = 9.3, 2.7 Hz, 1H), 7.36 (s, 1H), 6.45 (s, 1H). 13C NMR (126 MHz, DMSO-d6) δ 164.25, 152.17, 150.86, 142.52, 142.24, 139.69, 125.21, 124.33, 122.04, 120.49, 116.63, 108.86, 104.09 ESI-MS (negative mode): M/Z [M−H]− 323.0201.
(20) 3-chloro-4-[(5-chloro-2-hydroxybenzoyl)amino]-N-(3,4-dihydroxybenzyl)benzamide
Compound 20 was obtained using general procedure C starting from 6b (100 mg, 0.3 mmol) and 1-(3,4-dimethoxyphenyl)methanamine followed by general procedure D resulting in 52 mg (0.12 mmol) of white powder (39% over 2 steps).1H NMR (500 MHz, DMSO-d6) δ 12.37 (s, 1H), 11.11 (s, 1H), 8.98 (t, J = 6.0 Hz, 1H), 8.84 (s, 1H), 8.71 (s, 1H), 8.58 (d, J = 8.7 Hz, 1H), 8.14–8.06 (m, 1H), 7.99 (d, J = 2.9 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.53 (dd, J = 8.8, 2.9 Hz, 1H), 7.10 (d, J = 8.7 Hz, 1H), 6.73 (s, 1H), 6.67 (d, J = 8.0 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 4.31 (d, J = 5.8 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 164.50, 162.98, 155.77, 145.54, 144.64, 137.93, 134.11, 131.20, 130.70, 130.38, 128.71, 127.54, 124.03, 123.06, 121.80, 120.14, 119.61, 118.76, 115.77, 115.38, 42.83. ESI-MS: M/Z [M+H]+ 447.0510.
(21) 3-chloro-4-[(5-chloro-2-hydroxybenzoyl)amino]-N-[2-(3,4-dihydroxyphenyl)ethyl]benzamide
Compound 21 was obtained using general procedure C starting from 6b (100 mg, 0.3 mmol) and 2-(3,4-dimethoxyphenyl)ethan-1-amine followed by general procedure D resulting in 67 mg (0.15 mmol) of white powder (50% over 2 steps).1H NMR (500 MHz, DMSO-d6) δ 12.37 (s, 1H), 11.09 (s, 1H), 8.76 (s, 1H), 8.70–8.53 (m, 3H), 8.00 (d, J = 14.3 Hz, 2H), 7.87 (d, J = 8.7 Hz, 1H), 7.52 (d, J = 8.7 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.70–6.58 (m, 2H), 6.48 (d, J = 8.0 Hz, 1H), 3.41 (s, 2H), 2.66 (t, J = 7.5 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 164.62, 162.96, 155.76, 145.53, 144.00, 137.84, 134.08, 131.37, 130.66, 130.38, 128.61, 127.39, 124.04, 123.04, 121.78, 120.14, 119.70, 119.59, 116.46, 115.96, 41.85, 35.03. ESI-MS: M/Z [M+H]+ 461.0597.
NMR spectra can be found in supplementary materials.

3.3. Antibacterial Activity

3.3.1. Antimicrobial Susceptibility Assay

Bacterial samples for this research were sourced from the American Type Culture Collection (ATCC), the Canadian National Intensive Care Unit (CAN-ICU) surveillance study [22], and the Canadian Ward (CANWARD) surveillance study [23]. Clinical samples from the CAN-ICU and CANWARD studies were taken from patients with suspected infectious diseases in participating medical centers across Canada during the study period. The antibacterial properties of the compounds were evaluated using the microbroth dilution technique as per the Clinical and Laboratory Standards Institute (CLSI) guidelines [24]. Bacterial cultures were cultured overnight and then diluted in saline to a 0.5 McFarland standard. This was further diluted 1:50 in Cation-adjusted Mueller-Hinton broth (CAMHB) to yield a concentration of about 5 × 105 CFU/mL. Tests were conducted in 96-well plates. The agents were serially diluted in CAMHB and incubated with bacterial samples at 37 °C for 18 h. The minimum inhibitory concentration (MIC) was determined as the lowest concentration preventing visible bacterial growth, confirmed using an EMax Plus microplate reader (Molecular Devices, San Jose, CA, USA) at 590 nm. CAMHB, with or without bacterial cells, served as positive and negative controls, respectively.

3.3.2. Checkerboard Assay

The experiment was conducted in 96-well plates as described previously [25]. One agent underwent a 2-fold serial dilution along the x-axis, while the other was similarly diluted along the y-axis, resulting in a matrix where each well held both agents at varying concentrations. Bacterial cultures, cultivated overnight, were diluted in saline to achieve a 0.5 McFarland turbidity. This was then further diluted 1:50 in CAMHB, and each well was inoculated, reaching an approximate concentration of 5 × 105 CFU/mL. Wells containing only CAMHB, with or without bacteria, served as the positive and negative controls, respectively. The plates were incubated at 37 °C for 18 h and checked for visible turbidity, verified with an EMax Plus microplate reader (Molecular Devices, USA) at 590 nm. The fractional inhibitory concentration (FIC) for each agent was determined by dividing the MIC of the compound with colistin by its MIC when alone. Similarly, the FIC for colistin was determined by dividing its MIC with each compound by its standalone MIC. The FIC index was derived by adding both FIC values together. FIC indices were classified as synergistic (≤0.5), indifferent (0.5 < x ≤ 4), or antagonistic (>4).

3.4. Cell Proliferation Assay

Cell proliferation was assessed by quantifying changes in cell numbers using the CyQuant cell proliferation assay (Invitrogen, Waltham, MA, USA), essentially as described by the manufacturer. OVCAR-3 and COV362 cells were seeded in 96-well plates (7500 cells/well) in a volume of 100 µL. Wells with only media and no cells served as blanks. The plates were maintained in a 5% CO2 incubator at 37 °C. Two additional plates with cells and blank wells were prepared as control plates (did not receive the drug treatment) for determination of the cell numbers on the day of the addition of the drugs (day 0) and after the 48 h incubation absolute cell numbers from representative wells from these plates were determined with a Coulter ZM counter, while the remainder wells were processed for the CyQuant assay as described below. When cells were in the log phase, drug solutions were added to the test plates to yield final concentrations of 0–100 µM. The control plates received the media with the vehicle. After 48 h incubation, the media was removed, and the plates were placed at −80 °C for 7 days. The plates were allowed to thaw to room temperature, and CyQuant reagent in lysis buffer (200 µL) was added to each well. Fluorescence was measured on a SpectraMax M2 microplate reader (Molecular Devices, USA) at excitation and emission wavelengths of 480 and 520 nm, respectively. The results were expressed as percent cell number relative to initial cell number for each concentration.

4. Conclusions

A series of niclosamide analogs were synthesized to perform an SAR with an overall goal of replacing the nitro group of niclosamide to reduce toxicity while maintaining the ability of niclosamide to synergize with colistin against GNB. A small library of compounds was produced and their ability to synergize with colistin was observed. It was found that the nitro group on niclosamide can be replaced by an amine, a methyl ester, or an azide while still retaining colistin-potentiating activity. We also showed that the phenol group of niclosamide was necessary for synergy with colistin, but that the addition of multiple phenols led to a complete loss of synergy. The methyl ester analog (5a) was assessed against a panel of MDR clinical isolates and was shown to reduce colistin MIC to below CLSI breakpoint values, even against highly resistant isolates. The amine and methyl ester compounds were also found to be less toxic to eukaryotic cells. One significant challenge that needs to be overcome is the likely metabolic instability of the ester in compound 5a, as esters are known to be prone to hydrolysis in vivo [26], especially given that the carboxylic acid derivative 6 displayed no synergy with colistin. Nonetheless, this work provides important insights into synthetic strategies for the future development of new niclosamide derivatives, and that modification to the nitro group of niclosamide may be a viable strategy of reducing toxicity.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics13010043/s1, Figure S1–S42 NMR Spectra; Table S1 Minimum inhibitory concentration (MIC) in μg/mL of compounds 1–21 against 4 colistin-resistant strains of GNB. Table S2. Colistin minimum inhibitory concentration (MIC) in combination with 4 μM of compound 5b and niclosamide against 4 colistin-resistant strains of GNB.

Author Contributions

L.B.: Conceptualization, Investigation, Writing—original draft; Q.N.: Investigation, Writing—Review & Editing; R.A.: Investigation, Writing—Review & Editing; D.R.: Investigation, Writing—Review & Editing; M.B.: Investigation; R.D.: Conceptualization, Writing—Review & Editing; G.A.: Supervision, Writing—Review & Editing; F.S.: Supervision, Writing—Review & Editing. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded by the Natural Sciences and Engineering Research Council of Canada (NSERC) in the form of a discovery grant (2018-06047). L.B. acknowledges support from the University of Manitoba in the form of a University of Manitoba Graduate Fellowship.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within this manuscript and Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Theuretzbacher, U. Global Antimicrobial Resistance in Gram-Negative Pathogens and Clinical Need. Curr. Opin. Microbiol. 2017, 39, 106–112. [Google Scholar] [CrossRef] [PubMed]
  2. Brown, E.D.; Wright, G.D. Antibacterial Drug Discovery in the Resistance Era. Nature 2016, 529, 336–343. [Google Scholar] [CrossRef] [PubMed]
  3. Todd, R.; Kiehlbauch, J.; Chen, L.; Walters, M.; Kallen, A. Notes from the Field: Pan-Resistant New Delhi Metallo-Beta-Lactamase-Producing Klebsiella Pneumoniae—Washoe County, Nevada, 2016. MMWR Morb. Mortal Wkly. Rep. 2017, 66, 33. [Google Scholar] [CrossRef]
  4. Prasad, V.; Mailankody, S. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues after Approval. JAMA Intern. Med. 2017, 177, 1569. [Google Scholar] [CrossRef]
  5. Fernandes, P.; Martens, E. Antibiotics in Late Clinical Development. Biochem. Pharmacol. 2017, 133, 152–163. [Google Scholar] [CrossRef] [PubMed]
  6. Ejim, L.; Farha, M.A.; Falconer, S.B.; Wildenhain, J.; Coombes, B.K.; Tyers, M.; Brown, E.D.; Wright, G.D. Combinations of Antibiotics and Nonantibiotic Drugs Enhance Antimicrobial Efficacy. Nat. Chem. Biol. 2011, 7, 348–350. [Google Scholar] [CrossRef] [PubMed]
  7. Rajamuthiah, R.; Fuchs, B.B.; Conery, A.L.; Kim, W.; Jayamani, E.; Kwon, B.; Ausubel, F.M.; Mylonakis, E. Repurposing Salicylanilide Anthelmintic Drugs to Combat Drug Resistant Staphylococcus Aureus. PLoS ONE 2015, 10, e0124595. [Google Scholar] [CrossRef]
  8. Imperi, F.; Massai, F.; Pillai, C.R.; Longo, F.; Zennaro, E.; Rampioni, G.; Visc, P.; Leoni, L. New Life for an Old Drug: The Anthelmintic Drug Niclosamide Inhibits Pseudomonas Aeruginosa Quorum Sensing. Antimicrob. Agents Chemother. 2013, 57, 996–1005. [Google Scholar] [CrossRef]
  9. Domalaon, R.; Malaka De Silva, P.; Kumar, A.; Zhanel, G.G.; Schweizer, F. The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli. Antimicrob. Agents Chemother. 2019, 63, e02574-18. [Google Scholar] [CrossRef]
  10. Jara, M.O.; Warnken, Z.N.; Sahakijpijarn, S.; Thakkar, R.; Kulkarni, V.R.; Christensen, D.J.; Koleng, J.J.; Williams, R.O. Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution. Pharmaceutics 2022, 14, 2568. [Google Scholar] [CrossRef]
  11. Chen, W.; Mook, R.A.; Premont, R.T.; Wang, J. Niclosamide: Beyond an Antihelminthic Drug. Cell Signal. 2018, 41, 89–96. [Google Scholar] [CrossRef] [PubMed]
  12. Li, H.; Mattingly, A.E.; Jania, L.A.; Smith, R.; Melander, R.J.; Ernst, R.K.; Koller, B.H.; Melander, C. Benzimidazole Isosteres of Salicylanilides Are Highly Active Colistin Adjuvants. ACS Infect. Dis. 2021, 7, 3303–3313. [Google Scholar] [CrossRef] [PubMed]
  13. Copp, J.N.; Pletzer, D.; Brown, A.S.; Van der Heijden, J.; Miton, C.M.; Edgar, R.J.; Rich, M.H.; Little, R.F.; Williams, E.M.; Hancock, R.E.W.; et al. Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections. mBio 2020, 11, e02068-20. [Google Scholar] [CrossRef] [PubMed]
  14. Ngai, T.W.; Elfar, G.A.; Yeo, P.; Phua, N.; Hor, J.H.; Chen, S.; Ho, Y.S.; Cheok, C.F. Nitro-Deficient Niclosamide Confers Reduced Genotoxicity and Retains Mitochondrial Uncoupling Activity for Cancer Therapy. Int. J. Mol. Sci. 2021, 22, 10420. [Google Scholar] [CrossRef] [PubMed]
  15. Domalaon, R.; Okunnu, O.; Zhanel, G.G.; Schweizer, F. Synergistic Combinations of Anthelmintic Salicylanilides Oxyclozanide, Rafoxanide, and Closantel with Colistin Eradicates Multidrug-Resistant Colistin-Resistant Gram-Negative Bacilli. J. Antibiot. 2019, 72, 605–616. [Google Scholar] [CrossRef] [PubMed]
  16. Huisgen, R. 1,3-Dipolar Cycloadditions. Past and Future. Angew. Chem. Int. Ed. Engl. 1963, 2, 565–598. [Google Scholar] [CrossRef]
  17. Mook, R.A.; Ren, X.-R.; Wang, J.; Piao, H.; Barak, L.S.; Lyerly, H.K.; Chen, W. Benzimidazole Inhibitors from the Niclosamide Chemotype Inhibit Wnt/β-Catenin Signaling with Selectivity over Effects on ATP Homeostasis. Bioorganic Med. Chem. 2017, 25, 1804–1816. [Google Scholar] [CrossRef]
  18. Walkty, A.; Karlowsky, J.A.; Adam, H.J.; Lagace-Wiens, P.; Baxter, M.; Mulvey, M.R.; McCracken, M.; Poutanen, S.M.; Roscoe, D.; Zhanel, G.G. Frequency of MCR-1-Mediated Colistin Resistance among Escherichia Coli Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2008-2015). CMAJ Open 2016, 4, E641–E645. [Google Scholar] [CrossRef]
  19. Liu, Y.Y.; Wang, Y.; Walsh, T.R.; Yi, L.X.; Zhang, R.; Spencer, J.; Doi, Y.; Tian, G.; Dong, B.; Huang, X.; et al. Emergence of Plasmid-Mediated Colistin Resistance Mechanism MCR-1 in Animals and Human Beings in China: A Microbiological and Molecular Biological Study. Lancet Infect. Dis. 2016, 16, 161–168. [Google Scholar] [CrossRef]
  20. Shangguan, F.; Liu, Y.; Ma, L.; Qu, G.; Lv, Q.; An, J.; Yang, S.; Lu, B.; Cao, Q. Niclosamide Inhibits Ovarian Carcinoma Growth by Interrupting Cellular Bioenergetics. J. Cancer 2020, 11, 3454–3466. [Google Scholar] [CrossRef]
  21. Bittman, R.; Li, Z.; Samadder, P.; Arthur, G. Anticancer Activity of a Ceramide Analog Containing a Disulfide Linkage. Cancer Lett. 2007, 251, 53–58. [Google Scholar] [CrossRef]
  22. Zhanel, G.G.; DeCorby, M.; Adam, H.; Mulvey, M.R.; McCracken, M.; Lagacé-Wiens, P.; Nichol, K.A.; Wierzbowski, A.; Baudry, P.J.; Tailor, F.; et al. Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob. Agents Chemother. 2010, 54, 4684–4693. [Google Scholar] [CrossRef]
  23. Hoban, D.J.; Zhanel, G.G. Introduction to the CANWARD Study (2007–11). J. Antimicrob. Chemother. 2013, 68 (Suppl. S1), i3–i5. [Google Scholar] [CrossRef]
  24. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 28th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018; ISBN 1562389238. [Google Scholar]
  25. Berry, L.; Brizuela, M.; Jackson, G.; Schweizer, F. A Niclosamide-Tobramycin Hybrid Adjuvant Potentiates Cefiderocol AgainstP. Aeruginosa. RSC Med. Chem. 2021, 12, 1565–1573. [Google Scholar] [CrossRef]
  26. Wang, D.; Zou, L.; Jin, Q.; Hou, J.; Ge, G.; Yang, L. Human Carboxylesterases: A Comprehensive Review. Acta Pharm. Sin. B 2018, 8, 699–712. [Google Scholar] [CrossRef]
Antibiotics 13 00043 g001
Figure 1. Structures of niclosamide, rafoxanide, and proposed new scaffolds. The initial site of modification is highlighted.
Figure 1. Structures of niclosamide, rafoxanide, and proposed new scaffolds. The initial site of modification is highlighted.
Antibiotics 13 00043 g001
Antibiotics 13 00043 sch001
Scheme 1. Synthesis of amine derivatives of niclosamide (a) Zn, NH4Cl, MeOH/THF, rt (b) CH3COCl, DCM, rt (c) CH3I, 2,6 lutidine, DMF, rt.
Scheme 1. Synthesis of amine derivatives of niclosamide (a) Zn, NH4Cl, MeOH/THF, rt (b) CH3COCl, DCM, rt (c) CH3I, 2,6 lutidine, DMF, rt.
Antibiotics 13 00043 sch001
Antibiotics 13 00043 sch002
Scheme 2. Synthesis of azide, ester, and carboxylic acid derivatives of niclosamide. (a) EDC, THF, rt (b) PCl3, xylenes, reflux (c) LiOH (aq), THF/MeOH, rt.
Scheme 2. Synthesis of azide, ester, and carboxylic acid derivatives of niclosamide. (a) EDC, THF, rt (b) PCl3, xylenes, reflux (c) LiOH (aq), THF/MeOH, rt.
Antibiotics 13 00043 sch002
Antibiotics 13 00043 sch003
Scheme 3. Synthesis of amide derivatives of niclosamide (a) PCl3/xylenes, reflux; (b) LiOH (aq), THF/MeOH; (c) TBTU, NMM, DMF, NH2-R; (d) BBr3, DCM, 0 °C; (e) H2 Pd/C, MeOH/THF.
Scheme 3. Synthesis of amide derivatives of niclosamide (a) PCl3/xylenes, reflux; (b) LiOH (aq), THF/MeOH; (c) TBTU, NMM, DMF, NH2-R; (d) BBr3, DCM, 0 °C; (e) H2 Pd/C, MeOH/THF.
Antibiotics 13 00043 sch003
Antibiotics 13 00043 sch004
Scheme 4. Synthesis of triazole derivatives of niclosamide (a) CuI⋅P(OEt)3, iPr2Net, DMF, rt, 2 h.
Scheme 4. Synthesis of triazole derivatives of niclosamide (a) CuI⋅P(OEt)3, iPr2Net, DMF, rt, 2 h.
Antibiotics 13 00043 sch004
Antibiotics 13 00043 sch005
Scheme 5. Synthesis of polyphenol derivatives of niclosamide. (a) PCl3, xylenes, reflux (b) BBr3, DCM, 0 °C.
Scheme 5. Synthesis of polyphenol derivatives of niclosamide. (a) PCl3, xylenes, reflux (b) BBr3, DCM, 0 °C.
Antibiotics 13 00043 sch005
Antibiotics 13 00043 g002
Figure 2. Synergy comparison between compounds 1, 5a, or 4 and niclosamide. PA = Pseudomonas aeruginosa, KP = Klebsiella pneumoniae, EC = Escherichia coli. Red dotted line denotes FICI of 0.5. FICI values were obtained at a concentration of 4 μM for each compound.
Figure 2. Synergy comparison between compounds 1, 5a, or 4 and niclosamide. PA = Pseudomonas aeruginosa, KP = Klebsiella pneumoniae, EC = Escherichia coli. Red dotted line denotes FICI of 0.5. FICI values were obtained at a concentration of 4 μM for each compound.
Antibiotics 13 00043 g002
Antibiotics 13 00043 g003
Figure 3. Effect of niclosamide, compound 1 and compound 5a (0–100 µM) on ovarian cancer cell lines (a) OVCAR-3 and (b) COV362 cells. Cell numbers from representative wells were determined on day 0 before the addition of the compound. After 48 h incubation (day 2), cells were counted again to determine the increase in cell number over day 0 cell count. The overall increase in cell number for control after 48 h incubation was found to be around 26% and 89% relative to the initial cell number (day 0) for OVCAR-3 and COV362 cells, respectively. Each concentration of the drug tested is represented as a percent of that cell growth relative to the initial cell number. The results represent the mean ± standard deviation of two independent experiments with four wells for each concentration.
Figure 3. Effect of niclosamide, compound 1 and compound 5a (0–100 µM) on ovarian cancer cell lines (a) OVCAR-3 and (b) COV362 cells. Cell numbers from representative wells were determined on day 0 before the addition of the compound. After 48 h incubation (day 2), cells were counted again to determine the increase in cell number over day 0 cell count. The overall increase in cell number for control after 48 h incubation was found to be around 26% and 89% relative to the initial cell number (day 0) for OVCAR-3 and COV362 cells, respectively. Each concentration of the drug tested is represented as a percent of that cell growth relative to the initial cell number. The results represent the mean ± standard deviation of two independent experiments with four wells for each concentration.
Antibiotics 13 00043 g003
Table 1. Colistin MIC in combination with 4 μM of compounds 1–3 against four colistin-resistant strains of GNB. KP = Klebsiella pneumoniae, EC = Escherichia coli.
Table 1. Colistin MIC in combination with 4 μM of compounds 1–3 against four colistin-resistant strains of GNB. KP = Klebsiella pneumoniae, EC = Escherichia coli.
Antibiotics 13 00043 i001
Colistin MIC with 4 μM Compound (μg/mL)
CompoundRKP113250KP113254EC94393EC94474
NiclosamideNO20.250.50.250.5
1NH216320.52
2Antibiotics 13 00043 i002256256816
3Antibiotics 13 00043 i003256256816
Colistin MIC alone256256816
Table 2. Colistin MIC in combination with 4 μM of compounds 4–12 and 14–17 against four colistin-resistant strains of GNB. KP = Klebsiella pneumoniae, EC = Escherichia coli.
Table 2. Colistin MIC in combination with 4 μM of compounds 4–12 and 14–17 against four colistin-resistant strains of GNB. KP = Klebsiella pneumoniae, EC = Escherichia coli.
Antibiotics 13 00043 i004
Colistin MIC with 4 μM Compound (μg/mL)
CompoundR1R2KP113250KP113254EC94393EC94474
NiclosamideClNO20.250.50.250.5
4HN30.250.50.0160.25
5aClAntibiotics 13 00043 i005110.251
6ClAntibiotics 13 00043 i006256256816
7ClAntibiotics 13 00043 i007256256816
8ClAntibiotics 13 00043 i008256256816
9ClAntibiotics 13 00043 i009256256816
10ClAntibiotics 13 00043 i010256256816
11ClAntibiotics 13 00043 i011256256816
12ClAntibiotics 13 00043 i012256256816
14ClAntibiotics 13 00043 i013256256816
15ClAntibiotics 13 00043 i014256256816
16ClAntibiotics 13 00043 i015256256816
17ClAntibiotics 13 00043 i016256256816
Colistin MIC alone256256816
Table 3. Colistin MIC in combination with 4 μM of polyphenol compounds 18–21 against four colistin-resistant strains of GNB. KP = Klebsiella pneumoniae, EC = Escherichia coli.
Table 3. Colistin MIC in combination with 4 μM of polyphenol compounds 18–21 against four colistin-resistant strains of GNB. KP = Klebsiella pneumoniae, EC = Escherichia coli.
Antibiotics 13 00043 i017
Colistin MIC with 4 μM Compound (μg/mL)
CompoundR1R2R3KP113250KP113254EC94393EC94474
NiclosamideClHNO20.250.50.250.5
18HOHNO2256256816
19OHOHNO2256256816
20ClHAntibiotics 13 00043 i018256256816
21ClHAntibiotics 13 00043 i019256256816
Colistin MIC alone256256816
Table 4. Synergy between compound 5a and colistin against a panel of wild-type and clinical isolates of P. aeruginosa.
Table 4. Synergy between compound 5a and colistin against a panel of wild-type and clinical isolates of P. aeruginosa.
StrainMICColMICCombiMIC5aMICCombiFICIInterpretation
PAO110.25>2560.250.250 < x < 0.251Synergy
PA0950.250.016>256160.063 < x < 0.125Synergy
PA2590.250.25>25611.000 < x < 1.004Additive
PA2600.250.125>25610.500 < x < 0.504Additive
PA26410.25>2560.50.250 < x < 0.252Synergy
PA26240.25>25610.063 < x < 0.066Synergy
PA10003620.25>25610.125 < x < 0.129Synergy
PA10188540.5>25610.125 < x < 0.129Synergy
PA9143340.5>2560.250.125 < x < 0.126Synergy
PA10124310240.5>25610.0005 < x < 0.0045Synergy
Table 5. Synergy between compound 5a and colistin against a panel of wild-type and clinical isolates of A. baumannii.
Table 5. Synergy between compound 5a and colistin against a panel of wild-type and clinical isolates of A. baumannii.
StrainMICColMICCombiMIC5aMICCombiFICIInterpretation
A. baumannii ATCC 1797810.25>2560.250.250 < x < 0.251Synergy
A baumannii 11019340.5>2560.250.125 < x < 0.126Synergy
AB02710240.5>25610.0005 < x < 0.004Synergy
AB0310.250.015625>256160.063 < x < 0.125Synergy
LAC-40.250.25>25611.000 < x < 1.004Additive
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Berry, L.; Neale, Q.; Arora, R.; Ramirez, D.; Brizuela, M.; Domalaon, R.; Arthur, G.; Schweizer, F. Exploring Structure–Activity Relationships of Niclosamide-Based Colistin Potentiators in Colistin-Resistant Gram-Negative Bacteria. Antibiotics 2024, 13, 43. https://doi.org/10.3390/antibiotics13010043

AMA Style

Berry L, Neale Q, Arora R, Ramirez D, Brizuela M, Domalaon R, Arthur G, Schweizer F. Exploring Structure–Activity Relationships of Niclosamide-Based Colistin Potentiators in Colistin-Resistant Gram-Negative Bacteria. Antibiotics. 2024; 13(1):43. https://doi.org/10.3390/antibiotics13010043

Chicago/Turabian Style

Berry, Liam, Quinn Neale, Rajat Arora, Danyel Ramirez, Marc Brizuela, Ronald Domalaon, Gilbert Arthur, and Frank Schweizer. 2024. "Exploring Structure–Activity Relationships of Niclosamide-Based Colistin Potentiators in Colistin-Resistant Gram-Negative Bacteria" Antibiotics 13, no. 1: 43. https://doi.org/10.3390/antibiotics13010043

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop